SCREENING TEST FOR CHLAMYDIA TRACHOMATIS IN WOMEN

描述：(摘自申请者摘要)生殖器衣原体 沙眼衣原体感染是目前最常见的性传播方式 美国的疾病。尽管它通常相对无症状 并造成严重的后遗症，很容易治愈。因此，它是一种 广泛筛查的理想靶点。然而，当前的诊断 方法极其昂贵、耗时和费力。 密集的。LCI建议论证以下基本技术可行性 建立生殖器衣原体的量热推定筛查试验 适合临床人员现场使用的妇女感染情况 有着不同的训练和背景。LCI测试将是快速的， 简单，便宜，室温下稳定，紧凑，非常适合使用 在资源匮乏的情况下。在第二阶段，申请组织将 制定、优化和形成衣原体筛查试验。同相 LCI将通过许可证将成品商业化 与其一家企业营销合作伙伴达成协议。

DESCRIPTION: (Adapted from the applicants' abstract) Genital Chlamydia trachomatis infection is currently the most common Sexually Transmitted Disease in the United States. Although it is often relatively asymptomatic and causes serious sequelae, it is readily treatable. Therefore, it is an ideal target for widespread screening. However, current diagnostic methodologies are prohibitively expensive, time consuming and labor intensive. LCI proposes to demonstrate the basic technical feasibility of developing a calorimetric, presumptive screening test for genital Chlamydia infection in women which is suitable for on-site use by clinical personnel with different training and backgrounds. The LCI test will be rapid, simple, inexpensive, stable at room temperature, compact, and ideal for use in resource poor settings. In Phase II, the applicant organization will develop, optimize and format its screening test for Chlamydia. In Phase III, LCI will commercialize the finished product through a license arrangement with one of its corporate marketing partners.